Recent research has found that NAM, as a precursor for NAD+, can enhance the efficacy of tumor immunotherapy by promoting PD-L1 expression and boosting the anti-tumor activity of natural killer cells [13,14]. This evidence concerns the gene CD274 and neoplasm.